CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 30 enrolled
Drug / intervention
Latanoprost +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00572936
NCT00572936Phase 2Completed
CompareCT.gov

Circadian Rhythms of Aqueous Humor Dynamics in Humans

University of Nebraska·interventional·Posted Dec 13, 2007·Updated Oct 24, 2023

In Brief

A Phase 2 clinical trial evaluating Latanoprost, Dorzolamide, and 1 other intervention for Glaucoma. Completed, enrolled 30 participants across 1 site.

Detailed Summary

This study is designed to identify physiological, pharmacological and pathological circadian fluctuations in aqueous humor inflow and outflow, systemic blood pressure and ocular blood flow in humans.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlaucoma
CountriesUnited States
CollaboratorsPfizer

Timeline

Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 13, 2007
Enrollment StartMar 13, 2006
Primary CompletionNov 1, 2009
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 18.6 years ago

Interventions

Latanoprostdrug

prostaglandin

Dorzolamidedrug

carbonic anhydrase inhibitor

Timololdrug

beta blocker